Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

The Ionis Pharmaceuticals Analyst: Jason Gerberry downgraded the rating for Ionis Pharmaceuticals from Buy to Underperform, while reducing the price target from $40 to $30.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.